Beijing, China, September 1, 2026

Pyrotech Therapeutics has announced a major clinical development milestone for PTT-121, an investigational selective Gasdermin D (GSDMD) inhibitor, after dosing the first healthy volunteer in its Phase 1 clinical study. The milestone makes PTT-121 the first selective GSDMD inhibitor to enter human clinical development, marking an important step in efforts to therapeutically target the pyroptosis pathway. The clinical-stage biopharmaceutical company is initially developing PTT-121 for septic shock, a life-threatening condition associated with uncontrolled inflammatory responses and widespread cell death. China’s National Medical Products Administration (NMPA) granted clinical trial approval for PTT-121 on August 4, 2026.

PTT-121 Enters First-in-Human Clinical Testing

The Phase 1 study is designed as a single-center, randomized, double-blind, placebo-controlled clinical trial being conducted at Peking University Third Hospital. The study will evaluate the safety, tolerability, and pharmacokinetic profile of intravenously administered PTT-121 following single ascending dose (SAD) and multiple ascending dose (MAD) regimens. Approximately 84 healthy Chinese adults between 18 and 55 years of age are expected to participate. The primary endpoint is the incidence of treatment-emergent adverse events (TEAEs), while secondary assessments will include pharmacokinetic and biomarker analyses. The first subject dosing represents the transition of PTT-121 from preclinical development into human testing, where investigators will begin establishing its safety profile and understanding how the compound behaves in the body.

Selective GSDMD Inhibition Targets Pyroptosis


PTT-121 is designed to inhibit GSDMD, a key protein involved in pyroptosis, an inflammatory form of programmed cell death. Activation of GSDMD can lead to pore formation in cellular membranes and promote the release of inflammatory mediators, including cytokines associated with severe immune responses. Pyrotech is developing PTT-121 to directly interfere with GSDMD pore formation, with the aim of limiting downstream inflammatory signaling and pyroptotic cell death. The company describes GSDMD as a historically challenging or “undruggable” target because it is a membrane pore-forming protein without enzymatic activity or a conventional small-molecule binding pocket. According to Pyrotech, its proprietary discovery platform enabled development of a highly selective, potent, intravenously administered small-molecule GSDMD inhibitor.

Advertisement

cGxPJobs Banner

Preclinical Program Supports Septic Shock Development

The initial clinical indication for PTT-121 is septic shock, a severe manifestation of sepsis in which dysregulated host responses to infection can result in systemic inflammation, organ dysfunction, and potentially life-threatening complications. Pyrotech reports that PTT-121 demonstrated robust activity across multiple preclinical sepsis models, including suppression of inflammatory cytokine responses and reductions in mortality in animal studies. The company believes targeting GSDMD could provide a therapeutic approach that acts downstream of NLRP3 and other inflammasome pathways, potentially giving the mechanism broader relevance across inflammatory diseases. However, the current Phase 1 trial is being conducted in healthy volunteers and is primarily intended to establish safety, tolerability, pharmacokinetics, and biomarker effects; efficacy in septic shock will require subsequent patient studies. Beyond PTT-121, Pyrotech is also advancing an orally bioavailable GSDMD inhibitor intended for potential use in chronic inflammatory diseases associated with excessive IL-1β and IL-18 secretion, including conditions such as gout and hidradenitis suppurativa. The company expects this next-generation program to enter clinical development in 2027. The advancement of PTT-121 into Phase 1 therefore establishes an early clinical foundation for a broader GSDMD-targeted drug development strategy and could generate the first human clinical evidence for selective pharmacological modulation of this pathway.

Source: Pyrotech Therapeutics press release